Meeting
2014 ASCO Annual Meeting
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153.
Authors
Costantine Albany
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Costantine Albany , Nasser H. Hanna , Joel Picus , Ralph J. Hauke , Christopher A. Fausel , Ziyue Liu , Mary J. Brames , Lawrence H. Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
NCT01736917
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4594)
DOI
10.1200/jco.2014.32.15_suppl.tps4594
Abstract #
TPS4594
Poster Bd #
159B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
First Author: Lee S. Schwartzberg
Poster
2017 ASCO Annual Meeting
Fosaprepitant use in children and adolescents at Memorial Sloan Kettering Cancer Center.
First Author: Dazhi Liu
Poster
2011 ASCO Annual Meeting
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
First Author: P. J. Hesketh